NKGen Biotech, Inc.
NKGen Biotech, Inc. (NKGN): 2 pipeline candidates · ~1 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.8 months
D/E -1.31 · 100% dilution
Lead: Phase 1/Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for NKGen Biotech, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.8M
Cash
$29K
Quarterly Burn
$2.8M
Runway
0.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$193K
| Holder | Shares | Value |
|---|---|---|
| meteora capital, llc | 2,755,935 | $193K |
Frequently asked questions
How many drug candidates are in NKGen Biotech, Inc.'s pipeline?
NKGen Biotech, Inc. (NKGN) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NKGen Biotech, Inc.'s lead drug candidate?
NKGen Biotech, Inc.'s most advanced tracked candidate is snk01 (Phase 1/Phase 2) for Moderate Alzheimer Disease; Alzheimer Disease.
What is NKGen Biotech, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NKGen Biotech, Inc. has approximately 0.8 months of cash runway.
What is NKGen Biotech, Inc.'s market capitalization?
NKGen Biotech, Inc.'s market capitalization is approximately $7.8M.
Who is the CEO of NKGen Biotech, Inc.?
Dr. Paul Y. Song M.D. is the chief executive officer of NKGen Biotech, Inc. (NKGN).
Get the full picture on NKGen Biotech, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.